Who actually dies from prostate cancer? Additional observations

Earlier today we reported on a recent publication based on data from the CaPSURE registry database, which stated that, among men enrolled in that database, men died sooner from their prostate cancer after they progressed to having metastatic disease over time (median survival, 2.4 years from onset of metastasis) than died from their prostate cancer if they were initially diagnosed with metastatic disease (median survival, 5.3 years). … READ MORE …

Who actually dies from prostate cancer?

Some readers are probably going to find this very hard to believe, but … according to a newly published study, men initially diagnosed with metastatic prostate cancer are actually less likely to die from their cancer than men who are initially diagnosed with non-metastatic disease but who progress to having metastatic disease over time. … READ MORE …

Synergy between radiation of metastases and immunotherapy confirmed

Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. … READ MORE …

BET inhibition in treatment of mCRPC

A company called Zenith Epigenetics has recently reported data from a Phase I/II clinical trial of a drug known as ZEN003604 or ZEN-3694 in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have progressed on treatment with either abiraterone + prednisone or enzlautamide (Xtandi). … READ MORE …

New guidelines for management of advanced prostate cancer

The American Urological Association (AUA), together with the American Society for Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO), has just issued a new set of guidelines for the management of advanced prostate cancer (see here). … READ MORE …

Ipatasertib meets one of two primary endpoints in Phase III trial

According to a media release issued by Roche earlier this morning, the company’s investigational drug known as ipatasertib met one but not both of the two primary endpoints in a randomized, double-blind Phase III trial known as the IPATential150 trial. … READ MORE …

And now … FDA approves second PARP inhibitor for selected men with mCRPC

Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …

FDA approves first PARP inhibitor for selected men with mCRPC

Yesterday evening the US Food and Drug Administration (FDA) approved rucaparib (Rubraca) for the treatment of men with BRCA1/2-mutant, metastatic, castration-resistant prostate cancer (mCRPC) who have also already been treated with androgen receptor-directed therapy and taxane-based chemotherapy. … READ MORE …

More negative data for checkpoint inhibition in treatment of mCRPC

Alas … once again we hear that the combination of  androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clinically meaningful impact on the overall survival (OS) of men with metastatic, castration-resistant prostate cancer (mCRPC) compared to enzalutamide alone. … READ MORE …

Areas of consensus at APCCC last year … see Table 1

So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …

Why lutetium-177-PSMA treatment sometimes may not help, and may even harm

Lu-177-PSMA usually improves survival

We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>

FDA approves enzalutamide for treatment of metastatic HSPC

Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …

Data from the PROfound trial reported at ESMO

From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …

Cabazitaxel + carboplatin in treatment of mCRPC

A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …

The APCCC in Basel, Switzerland: Day 2

The second day of the APCCC here in Basel ran for 10 hours and encompassed a total of six sessions, as follows: … READ MORE …